Identification and Analysis of the Blood IncRNA Signature for Liver Cirrhosis and Hepatocellular Carcinoma

Qi Xia, Zheyue Shu, Ting Ye and Min Zhang

1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, 2 Key Laboratory for Biomedical Engineering of Ministry of Education, Zhejiang University, Hangzhou, China, 3 Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, Hangzhou, China

As one of the most common malignant tumors, hepatocellular carcinoma (HCC) is the fifth major cause of cancer-associated mortality worldwide. In 90% of cases, HCC develops in the context of liver cirrhosis and chronic hepatitis B virus (HBV) infection is an important etiology for cirrhosis and HCC, accounting for 53% of all HCC cases. To understand the underlying mechanisms of the dynamic chain reactions from normal to HBV infection, from HBV infection to liver cirrhosis, from liver cirrhosis to HCC, we analyzed the blood IncRNA expression profiles from 38 healthy control samples, 45 chronic hepatitis B patients, 46 liver cirrhosis patients, and 46 HCC patients. Advanced machine-learning methods including Monte Carlo feature selection, incremental feature selection (IFS), and support vector machine (SVM) were applied to discover the signature associated with HCC progression and construct the prediction model. One hundred seventy-one key HCC progression-associated IncRNAs were identified and their overall accuracy was 0.823 as evaluated with leave-one-out cross validation (LOOCV). The accuracies of the IncRNA signature for healthy control, chronic hepatitis B, liver cirrhosis, and HCC were 0.895, 0.711, 0.870, and 0.826, respectively. The 171-IncRNA signature is not only useful for early detection and intervention of HCC, but also helpful for understanding the multistage tumorigenic processes of HCC.

Keywords: hepatocellular carcinoma, hepatitis B virus, IncRNA, liver cirrhosis, support vector machine

INTRODUCTION

As one of the most common malignant tumors and the fifth major cause of cancer deaths worldwide (Jemal et al., 2011), hepatocellular carcinoma (HCC) is typical of highly invasive and metastatic potential. Although much progress has been made in clinical and experimental studies in HCC, the 5-year survival rate of HCC sufferers is still very low due to its poor prognosis, frequent clinical recurrence, and metastasis (Madkhali et al., 2015). The most important risk factors for liver cancer are hepatitis B virus (HBV), hepatitis C virus (HCV), excessive drinking, and exposure to aflatoxin B1. The geographical variability and heterogeneity of the incidence of HCC is different from the distribution of HBV and HCV infections on a global scale (Liu and Kao, 2007; Petruzzelli et al., 2016). Globally, HBV accounts for about 80% of virus-related HCC cases, especially in Africa and East Asia, where the incidence of HCC is the highest. In low-incidence HCC areas such as Western...
Europe and North America, HCV infection accounts for about 20% of the total number of HCCs. HBV seems to be mainly related to the development of HCC (Blachier et al., 2013; Mittal and El-Serag, 2013; Kew, 2014; Ozalkol, 2017). About 15–40% of chronically infected people develop severe sequelae, such as cirrhosis, liver failure, and liver cancer, and nearly 1 million people die each year due to complications related to HBV1.

Hepatitis B virus infection facilitates virus-induced immune response through releasing cytokines and genotoxic reactive oxygen species, which triggers hepatocyte necrosis and may eventually contribute to the development of carcinogenesis with the speed-up of the hepatocyte cell cycles and raised risk of genetic variation (Budhu and Wang, 2006). Therefore, suppression of viral replication via antiviral therapy appears to decrease the risk of cirrhosis and HCC (Liaw et al., 2004; Hosaka et al., 2013). HCC in the early phase can be effectively treated through liver transplantation, resection, or ablation, whereas the treatment strategies are very limited for advanced patients (Llovet, 2014). Accordingly, comprehensive approaches to identify and validate novel markers are needed so as to provide a new idea for the early diagnosis and exploration of therapeutic targets of HCC.

Recently, loads of dysregulated long non-coding RNAs (lncRNAs) have been confirmed in HCC tumor tissue via high-throughput sequencing techniques, some of which may serve as early diagnostic biomarkers or therapeutic targets for HCC (Huo et al., 2017). LncRNAs are a subclass of non-coding RNAs that are able to modulate gene expression and cancer-related signaling pathways. Sufficient evidence suggested that lncRNAs are correlated with HCC cell biological functions, such as cell proliferation, cell apoptosis, epithelial–mesenchymal transition (EMT) process, cell invasion, and tumor metastasis, and eventually result in the occurrence and progression of HCC (Qiu et al., 2017). For example, upregulation of several lncRNAs, including LncTGF-7, DANCR, ZEB1-AS1, and EGFR-AS1, have been proven to play crucial roles in HCC progression via the activation of EMT and Wnt/β-catenin signaling (Yuen et al., 2009; Wang et al., 2015; Qi et al., 2016; Yuan et al., 2016). Downregulated lncRNA H19 has been shown to be associated with HCC metastasis (Zhang et al., 2013). Despite the fact that increasing studies have reported dysregulated lncRNAs in HCC, most of corresponding mechanisms and potential functions remain unclear. Further explorations on the regulation of these dysregulated lncRNAs, their mechanisms, and their association with the etiology of HCC may facilitate us to find more specific and sensitive markers to control HCC.

To identify the lncRNA signature associated with HCC progression, we analyzed the blood lncRNA expression profiles of 38 healthy control samples, 45 chronic hepatitis B patients, 46 liver cirrhosis patients, and 46 HCC patients. Advanced machine-learning methods like support vector machine (SVM), Monte Carlo feature selection, and incremental feature selection (IFS) were implemented for identification of the HCC progression-associated signature and construction of the prediction model.

1https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/

MATERIALS AND METHODS

The IncRNA Expression Profiles of Patients From Different Tumorigenesis Stages

We downloaded the blood lncRNA expression profiles of 38 healthy control samples, 45 chronic hepatitis B patients, 46 liver cirrhosis patients, and 46 HCC sufferers from GSE78160 included in the Gene Expression Omnibus (GEO). Expression levels of 2,520 IncRNA probes were assessed by State Key Laboratory Human IncRNA array 2412 (GPL21494) developed by State Key Laboratory of Oncology in South China, Sun Yat-sen University. We would like to compare the differences among different tumorigenesis stages of HCC.

The Importance of IncRNAs Is Calculated Using the Monte Carlo Feature Selection Method

The Monte-Carlo feature selection (Draminski et al., 2008) was employed to identify the key HCC lncRNAs. It is a widely used method with excellent performance in finding key features (Chen et al., 2018b,c; Pan et al., 2019). Monte Carlo feature selection can evaluate the importance of a feature by considering the contribution of the feature to accurate classification through a series of decision trees. Three steps are included: First, it will randomly choose many feature subsets; then, on each feature subset, a tree classifier will be built; and last, based on these trees, a compressive feature importance score will be calculated (Chen et al., 2018a; Pan et al., 2018; Wang et al., 2018). The final feature-importance score will consider both the frequency of this feature being selected by a tree and how well the node of this feature on the tree can classify the samples.

To introduce the details of this algorithm, the total number of IncRNAs was represented by d, which was 2,520 in this study. Each time, m IncRNAs (m ≪ d) are chosen at random and a tree classifier t is trained and tested on the basis of the randomly divided patients in the training and the test groups. This procedure will repeat s times. At last, there will be a series of trees. On the basis of the times the IncRNA g selected through these trees and the contribution of this IncRNA g to the tree classification, the relative importance (RI) of the IncRNA g can be calculated as follows:

\[
RI_g = \sum_{\tau=1}^{s} (wAcc)^u \sum_{\tau_g(\tau)} IG(g_{\tau}(\tau)) \left( \frac{\text{no. in } n_{\tau}(\tau)}{\text{no. in } \tau} \right)^v
\]

where \(wAcc\) refers to the weighted classification accuracy of the decision tree \(\tau\); \(IG(g_{\tau}(\tau))\) represents the information gained by node \(n_{\tau}(\tau)\), a decision rule based on IncRNA g expression; \(\text{no. in } n_{\tau}(\tau)\) stands for the total number of patients in node \(n_{\tau}(\tau)\); \(\text{no. in } \tau\) refers to the total number of patients under the decision tree \(\tau\); and \(u\) and \(v\) represent the adjusted parameters.

2https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL21494
With Eq. (1), all IncRNAs will have a RI score and they will be ranked in line with their importance. The Monte Carlo feature selection method was implemented using the dmLab software (Draminski et al., 2008) accessed at https://home.ipipan.waw.pl/m.draminski/mcfs.html.

**Optimization of the IncRNA Signature With IFS Method**

To optimize the number of selected IncRNAs, the IFS method (Jiang et al., 2013; Li et al., 2014; Shen et al., 2014; Zhang et al., 2015; Huang et al., 2015; Zhang P.W. et al., 2015; Chen L. et al., 2017) was employed. IFS can help determine how many features should be chosen. It assesses the performance of a series of SVM classifiers using various numbers of IncRNAs from one IncRNA, two IncRNAs, three IncRNAs to more IncRNAs. The SVM was a widely used classifier that was wrapped into IFS to evaluate the classification performance of different IncRNA sets. The IncRNA combination that had the best performance will be selected. It made the selection procedure objective and the chosen signatures had optimal performance.

In this study, the SVM classifier was established using the R function svm from package e1071 with default parameters (SVM-Type: C-classification; SVM-Kernel: radial; cost: 1) and the classification accuracy was assessed with the aid of the leave-one-out cross-validation (LOOCV) method and then used to represent the prediction performance.

**RESULTS AND DISCUSSION**

**The HCC Progression IncRNAs Identified With Machine Learning Methods**

The IncRNA importance was evaluated with the Monte Carlo feature selection method. It reflected how well the expression level of this IncRNA can correctly classify the healthy control samples, chronic hepatitis B patients, liver cirrhosis patients, and HCC patients. The rank of this importance provided basis for further optimization.

We optimized the top 500 ranked IncRNAs to 171 IncRNAs using the IFS method. Figure 1 shows the IFS curve in which the abscissa is the count of IncRNAs responsible for the establishment of the SVM classifier, and the vertical coordinate is the prediction accuracy assessed by LOOCV. The IFS curve peaked at (171, 0.823), which meant when 171 IncRNAs were used and the accuracy was the highest as 0.823. The accuracies of healthy control, chronic hepatitis B, liver cirrhosis, and HCC were 0.895, 0.711, 0.870, and 0.826, respectively. The 171 IncRNA probes are listed in Supplementary Table 1. The confusion matrix of the prediction performance using these 171 IncRNAs are listed in Table 1. It depicts that not only the overall accuracy, but also the accuracy of each progression stage.

**The Biological Functions of the Identified IncRNAs**

Since the IncRNA array was customized and did not have too much annotation, we blasted their sequences onto the IncRNA sequences in LNCipedia, version 5.0 (Volders et al., 2018). Some of the identified IncRNAs were seen to be promising and may help understand the mechanisms underlying HCC tumorigenesis.

**LUCAT1**:20 ranked sixth in Supplementary Table 1. LUCAT1 (Lung Cancer Associated Transcript 1) was seen to be elevated in HCC tissue and cells relative to that in adjacent tissue, which was associated with pathological characteristics, such as tumor size, metastasis, and stage of HCC (Levine et al., 1988). Functional studies have unveiled the active role of LUCAT1 both in vitro and in vivo in potentiating the HCC tumor progression and metastasis (Levine et al., 1988; Gramantieri et al., 2018). LUCAT1 was also reported to bind to Annexin A2 (ANXA2) specifically, which is a phospholipid binding protein dependent on calcium and plays a vital role in the malignant behaviors of HCC cells with its expression elevated (Shi et al., 1993; Kohli et al., 2018). Zhang F. et al. (2015) indicated that the knock down of ANXA2 induced by shRNA inhibits hepatoma cell invasive and migratory capabilities and may hence become a therapeutic target for the molecular treatment of HCC in the future.

Lnc- RAP2B-5:1 ranked ninth in Supplementary Table 1. RAP2B, an Ras oncogene family (small GTP-binding proteins) member (Ohmstede et al., 1990), is a novel target of p53 regulating the cell pro-survival function (Qu et al., 2016). Increasing evidence suggests a critical role of RAP2B in the regulation of cytoskeletal organization, cell growth, cell proliferation, and other cellular processes (Uechi et al., 2009; Qu et al., 2016). Zhang et al. (2017) discovered the elevated expression of RAP2B in HCC tissue and cell lines, and revealed that the decreased RAP2B significantly downregulates the levels of p-FAK and MMP-2, and then inhibits HCC cell proliferation, invasion, and migration. Thus, Rap2B-targeted anticancer drugs are expected to become a novel therapy against cancer.

Lnc-FOXO1-2:3 ranked 15th in Supplementary Table 1. Forkhead Box Protein O1 (FOXO1), a member of the forkhead family, has been discovered to be dysregulated in multiple cancers including HCC, and it affects many cellular processes, like carcinogenesis, DNA damage repair, cell apoptosis, and tumor immunity (Huang and Tindall, 2007; Luo et al., 2016). It’s reported that higher FOXO1 significantly promotes replication and expression of HBV (Wang and Tian, 2017) and is related to a more favorable prognosis of HCC (Calvisi et al., 2009; Leung et al., 2015). EMT, a crucial process amid the occurrence of metastasis, is the principal reason for mortality in HCC (Papageorgis, 2015; Ye and Weinberg, 2015). Dong et al. (2017) found that FOXO1 is capable of reversing the EMT process through directly inhibiting transcription inducers like ZEB2, indicating the negative effect of FOXO1 on HCC cell proliferation and invasion. ZEB2 is reported to be upregulated in HCC cell-derived lung metastatic nodules, and its overexpression is responsible for HCC recurrence.

---

Supplementary Table 1

| IncRNA Name | Rank |
|-------------|------|
| LUCAT1      | 6    |
| RAP2B       | 9    |
| FOXO1       | 15   |

---

3https://CRAN.R-project.org/package=e1071

4https://lncipedia.org/
FIGURE 1 | The IFS curve for key lncRNA selection. The x-axis is the number of lncRNAs used to build the SVM classifier. The y-axis is the prediction accuracy evaluated with LOOCV. When 171 lncRNAs were used, the accuracy was the highest as 0.823.

TABLE 1 | The confusion matrix of the prediction performance using 171 lncRNAs.

| Actual stage 1 | Predicted stage 1 | Predicted stage 2 | Predicted stage 3 | Predicted stage 4 | Accuracy of each stage |
|----------------|-------------------|-------------------|-------------------|-------------------|------------------------|
| Actual stage 1 | 34                | 3                 | 0                 | 1                 | 34/(34 + 3 + 0 + 1) = 0.895 |
| Actual stage 2 | 3                 | 32                | 8                 | 2                 | 32/(3 + 32 + 8 + 2) = 0.711 |
| Actual stage 3 | 0                 | 5                 | 40                | 1                 | 40/(0 + 5 + 40 + 1) = 0.870 |
| Actual stage 4 | 1                 | 7                 | 0                 | 38                | 38/(1 + 7 + 0 + 38) = 0.826 |

stage 1, healthy control; stage 2, chronic hepatitis B; stage 3, liver cirrhosis; stage 4, hepatocellular carcinoma.

(Xia et al., 2014; Yang et al., 2015). Therefore, the enhancement of FOXO1 and the inhibition of EMT-related inducers like ZEB2 may have the potential to be applied in the clinical treatment of HCC with great value.

MALAT1:17 ranked 104th in Supplementary Table 1. As a long and highly conserved lncRNA widely expressed in different tissues (Zebisch et al., 2016), metastasis-associated lung adenocarcinoma transcription 1 (MALAT1) is regarded to be closely related to diverse cancer types, especially in the progression of HCC related to HBx (Jiang et al., 2014; Hou et al., 2017; He et al., 2019). The lncRNA—MALAT1 has been reported to be increased in HCC cell lines and it serves as a proto—oncogene amid the progression of HCC by means of activating the Wnt pathway and inducing the oncogenic splicing factor SRSF1 (Malakar et al., 2017). Furthermore, Liu et al. (2018) found that knockdown of MALAT1 suppresses the growth, migration, and motility of HCC cells by elevating miR-195, indicating that MALAT1 is an important player in the progression of HCC.

In addition to the aforementioned genes, lncRNAs including EPCAM (Yamashita et al., 2008), WDR5 (Cui et al., 2018), S1PR1 (Zhou et al., 2014), HMGA1 (Andreozzi et al., 2016), TGFBR2 (Chen Y.L. et al., 2017), CXCL12 (Semaan et al., 2017), and SENP2 (Shen et al., 2012) were also reported to participate in the pathogenesis of liver cirrhosis and HCC. Zhang et al. (2019) confirmed that silencing EPCAM can inhibit hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis through the PI3K/Akt/mTOR signaling pathway. Wenfang Tian et al. (2016) also found that WDR5 is an important epigenetic factor in the process of liver fibrosis. S1PR1 has been reported to be associated with cholestatic liver injury in early stage
liver cancer and may be a potential target for the prevention of drug-induced cholestatic liver injury (Yang et al., 2017). HMGA1 was confirmed to be involved in the proliferation and invasion of HCC cells through the ilk/Akt/GSK3 signaling pathway (Liu et al., 2017). TGFBR2 is involved in regulating the regulation axis and aggravates liver fibrosis (Fu et al., 2020). The CXCL12/CXCR4 biological axis can inhibit the activation and migration of hepatic stellate cells in vitro and in vivo (Qin et al., 2018). SENP2 can reduce CCl4-induced liver fibrosis by promoting apoptosis and reversion of activated hepatic stellate cells (Bu et al., 2018).

Three lncRNAs mentioned earlier have been found to be associated with HBV. Studies have shown that MALAT1, WDR5, and CXCL12 are involved in the regulation of HCC induced by HBV through epigenetic mechanism. Bo He et al. (2019) found that interaction of lncRNA-MALAT1 and miR-124 regulates HBx-induced cancer stem cell properties through PI3K/Akt signaling. Weiwu Gao et al. found that WDR5 plays an important role in HBV-driven mouse hepatocyte proliferation and tumor growth (Gao et al., 2020). Chao Wang et al. (2017) found that HBx also upregulated the translocation of MDM2 into the nucleus and enhanced the transcriptional activity of CXCL12 and CXCR4.

Though the role of lncRNAs in HCC has been partially revealed, more large cohort studies and in-depth functional studies are still needed to validate the HCC lncRNA signature and to investigate the underlying mechanisms. In future research, we will focus on the biological functions of these lncRNAs in HBV infection, liver cirrhosis, and liver cancer, and further explore the molecular regulatory mechanism of these lncRNAs in cells to clarify the mechanism of lncRNAs and their important position in cells.

CONCLUSION

Tumorigenesis is a multistage process. HBV infection is a trigger factor for liver cirrhosis and liver cirrhosis is a transition stage to HCC. The dynamic changes from normal to HBV infection, from HBV infection to liver cirrhosis, from liver cirrhosis to HCC, formed the chain reaction of tumorigenesis. We analyzed the blood lncRNA expression profiles of different HCC progression stages: healthy, chronic hepatitis B, liver cirrhosis patients, and HCC. A 171-lncRNA signature was identified with advanced machine-learning methods. These lncRNAs can help explain the mechanisms of HCC tumorigenesis. They can be used as biomarkers of HCC progression to monitor how bad the situation is and provide early detection and intervention of HCC.

DATA Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

QX, MZ, ZS, and TY all contributed to the study design and the final manuscript. They all gave the final approval of the version to be submitted. All authors read and approved the final manuscript.

FUNDING

This study was supported in part by Ministry of Science and Technology of the People's Republic of China, 13th Five-Year National Science and Technology Major Project (2018ZX10715-013-003). It focused on Research on Intelligent Medical Application of Information Platform of Integrated Prevention and Control Demonstration Area Based on "Internet +", Ministry of Science and Technology of the People's Republic of China, 13th Five-Year National Key Research and Development Program of China, 2019YFC0840600 and 2019YFC0840609. Research on cloud platform and intelligent diagnosis and treatment technology for viral hepatitis diagnosis and treatment.

SUPPLEMENTARY MATERIAL

The Supperimentary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2020.595699/full#supplementary-material

Supplementary Table 1 | The 171 lncRNA probes associated with HCC progression.

REFERENCES

Andreozzi, M., Quintavalle, C., Benz, D., Quagliata, L., Matter, M. S., Calabrese, D., et al. (2016). HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in vitro models. Neoplasia 18, 724–731. doi: 10.1016/j.neo.2016.10.002
Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D. C., and Roudot-Thoraval, F. (2013). The burden of liver disease in Europe: a review of available epidemiological data. J. Hepatol. 58, 593–608. doi: 10.1016/j.jhep.2012.12.005
Bu, F. T., Chen, Y., Yu, H. X., Chen, X., Yang, Y., Pan, X. Y., et al. (2018). SENP2 alleviates CCl4-induced liver fibrosis by promoting activated hepatic stellate cell apoptosis and reversion. Toxicol. Lett. 289, 86–98. doi: 10.1016/j.toxlet.2018.03.010
Budiu, A., and Wang, X. W. (2006). The role of cytokines in hepatocellular carcinoma. J. Leukocyte Biol. 80, 1197–1213. doi: 10.1189/jlb.0506297
Calvisi, D. F., Ladu, S., Pinna, F., Frau, M., Tomasi, M. L., Sini, M., et al. (2009). SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 137, 1816–1826.e1–10. doi: 10.1053/j.gastro.2009.08.005
Chen, L., Li, J., Zhang, Y. H., Feng, K., Wang, S., Zhang, Y., et al. (2017). Identification of gene expression signatures across different types of neural stem cells with the Monte-Carlo feature selection method. J. Cell Biochem. 119, 3394–3403. doi: 10.1002/jcb.26507
Chen, L., Li, J., Zhang, Y. H., Feng, K., Wang, S., Zhang, Y., et al. (2018a). Identification of gene expression signatures across different types of neural stem cells with the Monte-Carlo feature selection method. J. Cell Biochem. 119, 3394–3403. doi: 10.1002/jcb.26507
Chen, L., Pan, X., Zhang, Y. H., Kong, X., Huang, T., and Cai, Y. D. (2018b). Tissue differences revealed by gene expression profiles of various cell lines. J. Cell Biochem. 120, 7068–7081. doi: 10.1002/jcb.27977

Chen, L., Zhang, S., Pan, X., Hu, X. H., Zhang, Y. H., Yuan, F., et al. (2018c). HIV infection alters the human epigenetic landscape. Gene. Ther. 26, 29–39. doi: 10.1016/j.gene.2018.01.015-6

Chen, Y. L., Xu, Q. P., Guo, F., and Guan, W. H. (2017). MicroRNA-30d2 downregulates TGFBR2 expression and promotes hepatocellular carcinoma growth and invasion. Exp. Ther. Med. 13, 681–687. doi: 10.3892/etm.2016.3970

Cui, Z., Li, H., Mu, C., Mu, Y., Zhang, X., et al. (2018). Effect of high WDR5 expression on the hepatocellular carcinoma prognosis. Oncol. Lett. 15, 7864–7870. doi: 10.3828/ol.2018.8298

Dong, T., Zhang, Y., Chen, Y., Liu, P., An, T., Zhang, J., et al. (2017). FOXO1 inhibits the invasion and metastasis of hepatocellular carcinoma by reversing ZEB2-induced epithelial-mesenchymal transition. Oncotarget 8, 1703–1713. doi: 10.18632/oncotarget.13786

Draminski, M., Rada-Iglesias, A., Enroth, S., Wadelius, C., Koromakci, I., and Komorowski, J. (2008). Monte Carlo feature selection for supervised classification. Bioinformatics 24, 110–117. doi: 10.1093/bioinformatics/btn486

Fu, X., Qie, J., Fu, Q., Chen, J., Yin, Y., and Ding, Z. (2020). miR-20a-5p/TGFBR2 axis affects pro-inflammatory macrophages and aggravates liver fibrosis. Front. Oncol. 10:107. doi: 10.3389/fonc.2020.00107

Gao, W., Jia, Z., Tian, Y., Yang, P., Sun, H., Wang, C., et al. (2020). HBx protein contributes to liver carcinogenesis by H3K4me3 modification through stabilizing WD repeat domain 5 protein. Hepatology 71, 1678–1695. doi: 10.1002/hep.30947

Gramantieri, L., Baglioni, M., Fornari, F., Laginestra, M. A., Ferracin, M., Indio, V., et al. (2018). LncRNAs as novel players in hepatocellular carcinoma recurrence. Oncotarget 9, 35085–35099. doi: 10.18632/oncotarget.26202

He, B., Peng, F., Li, W., and Jiang, Y. (2019). Interaction of IncRNA-MALAT1 and miR-124 regulates HBx-induced cancer stem cell properties in HepG2 cells through PI3K/Akt signaling. J. Cell Biochem. 120, 2908–2918. doi: 10.1002/jcb.26823

Hosaka, T., Suzuki, F., Kobayashi, M., Seko, Y., Kawamura, Y., Zeks, H., et al. (2013). Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58, 98–107. doi: 10.1002/hep.26180

Hou, Z., Xu, X., Fu, X., Tao, S., Zhou, J., Liu, S., et al. (2017). HBX-related long non-coding RNA MALAT1 promotes cell metastasis via up-regulating ITGBP3 in hepatocellular carcinoma. Am. J. Cancer Res. 7, 845–856.

Huang, T., and Tindall, D. J. (2007). Dynamic FoxO transcription factors. J. Cell Sci. 120(Pt 15), 2479–2487. doi: 10.1242/jcs.011222

Huang, T., Shu, Y., and Cai, Y.-D. (2015). Genetic differences among ethnic groups. BMC Genomics 16, 1093. doi: 10.1186/s12864-015-2328-0

Huo, X., Han, S., Xu, S., Zhang, J., Wei, P., Zhao, Y., et al. (2017). LncRNA MALAT1 promotes cell metastasis via up-regulating ITGBP3 in hepatocellular carcinoma. J. Gastrointest Cancer 48, 238–240. doi: 10.3748/wjg.v22.i34.7824

Jia et al. Identification of IncRNA Signature for HCC...
Shen, H. J., Zhu, H. Y., Yang, C., and Ji, F. (2012). SENP2 regulates hepatocellular carcinoma cell growth by modulating the stability of beta-catenin. *Asian Pacific J. Cancer Prevent. APJCP* 13, 3583–3587. doi: 10.7314/apjcp.2012.13.8.3583

Shi, H., Xiao, L., Duan, W., He, H., Ma, L., Da, M., et al. (1993). ANXA2 enhances the progression of hepatocellular carcinoma via remodeling the cell motility associated structures. *Micron* 16, 26–33. doi: 10.1016/j.micron.2016.03.008

Shu, Y., Zhang, N., Kong, X., Huang, T., and Cai, Y. D. (2014). Predicting A-to-I RNA editing by feature selection and random forest. *PLoS One* 9:e110607. doi: 10.1371/journal.pone.0110607

Tian, W., Fan, Z., Li, J., Hao, C., Li, M., Xu, H., et al. (2016). Myocardin-related transcription factor A (MRRT-F-A) plays an essential role in hepatic stellate cell activation by epigenetically modulating TGF-beta signaling. *Int. J. Biochem. Cell Biol.* 71, 35–43. doi: 10.1016/j.biocell.2015.12.005

Uchii, Y., Bayarjargal, M., Umikawa, M., Oshiro, M., Takei, K., Yamashiro, Y., et al. (2009). Rap2 function requires palmitoylation and recycling endosome localization. *Biochem. Biophys. Res. Commun.* 378, 732–737. doi: 10.1016/j.bbrc.2008.11.107

Volders, P.-J., Anckaert, J., Vandesompele, J., Verheggen, K., Nuytens, J., Martens, V., et al. (2015). The long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepressing CTNNB1. *Hepatology* 63, 499–511. doi: 10.1002/hep.27893

Yuen, M. F., Tanaka, Y., Fong, D. Y., Fung, J., Wong, D., Yuen, J., et al. (2009). Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. *J. Hepatol.* 50, 80–88. doi: 10.1016/j.jhep.2008.07.023

Zebisch, A., Hatzl, S., Pichler, M., Wollmer, A., and Sill, H. (2016). Therapeutic resistance in acute myeloid leukemia: the role of non-coding RNAs. *Int. J. Mol. Sci.* 17:2080. doi: 10.3390/ijms17122080

Zhang, F., Wang, Z., Yuan, J., Wei, X., Tian, R., and Niu, R. (2015). RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway. *Breast Cancer Res. Treat.* 153, 263–275. doi: 10.1007/s10549-015-3529-6

Zhang, L., Duan, H. B., and Yang, Y. S. (2017). Knockdown of Rap2B inhibits the proliferation and invasion in hepatocellular carcinoma cells. *Oncol. Res.* 25, 19–27. doi: 10.3727/096504016x14685034103914

Zhang, L., Yang, F., Yuan, J. H., Yuan, S. X., Zhou, W. P., Luo, X. S., et al. (2013). Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. *Carcinogenesis* 34, 577–586. doi: 10.1093/carcin/bgs381

Zhang, N., Huang, T., and Cai, Y. D. (2014). Discriminating between deleterious and neutral non-frameshifting indels based on protein interaction networks and hybrid properties. *Mol. Genet. Genomics* 290, 343–352. doi: 10.1007/s00438-014-0922-5

Zhang, P. W., Chen, L., Huang, T., Zhang, N., Kong, X. Y., and Cai, Y. D. (2015). Classifying ten types of major cancers based on reverse phase protein array profiles. *PLoS One* 10:e0123147. doi: 10.1371/journal.pone.0123147

Zhang, Z., Wen, H., Weng, J., Feng, L., Liu, H., Xu, E., et al. (2019). Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway. *Cell Cycle* 18, 2239–2254. doi: 10.1080/15384101.2019.1642067

Zhou, P., Huang, G., Zhao, Y., Zhong, D., Xu, Z., Zeng, Y., et al. (2014). MicroRNA-363-mediated downregulation of SIP1 suppresses the proliferation of hepatocellular carcinoma cells. *Cell. Signal.* 26, 1347–1354.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.